Navigation Links
Huntington's disease discovery provides new hope for treatment
Date:7/28/2010

Australian scientists have identified the behaviour of the mutant protein 'huntingtin' which leads to the fatal Huntington's disease providing potential targets to treat the disease, a University of Melbourne study reveals.

Huntington's disease is a genetic disease with no cure, characterized by a steady decline in motor control and the dysfunction and death of brain cells. The cause of the disease has long baffled scientists.

Symptoms tend to first appear when the person is in their thirties or forties. The most common symptom is jerky movements of the arms and legs. A person with Huntington's disease may also have difficulties with speech, swallowing and concentration.

Using state of the art technology, Dr Danny Hatters and his colleagues at the University of Melbourne's Department of Biochemistry and Molecular Biology at the Bio 21 Institute observed how human mutant 'huntingtin' proteins form into large clumps, which kills brain cells and leads to progressed Huntington's disease.

"Steps prior to the clustering of the mutated proteins were thought to damage cells, but these steps were not clearly detectable under a microscope," Dr Hatters says.

"Understanding this process and finding the right target to block the ultimate death of the brain cells has been extremely difficult to determine," he says.

The technology called analytical ultracentrifugation and the methodology the researchers developed enabled them to visualize this process in much greater detail.

"What we have shown and are the first to show, is that mutated huntingtin protein forms three different sized clusters in the damaged cells," he says.

"This discovery will help to develop a targeted treatment that shuts down the key processes causing the clusters to form and for the disease to progress."

While researchers previously thought that small clusters of the mutant protein kept accumulating over time until they overwhelmed and killed the brain cells, Dr Hatters' team found that these clusters were static, which means they form in a more unpredictable manner than previously thought.

The discovery reveals the clusters place a steady stress on cells over time rather than steadily building up over time to some critical "toxic" level as previously thought.

"Why it takes so long for the cells to die in human disease is not known - however it could be that cells eventually cannot compensate anymore from the process where toxicity is built up to form one cluster called oligomers," he says.

"The real key of our work is that we now have direct targets in the critical steps in the process of cell toxicity and death and to gauge any therapeutic effects of drugs on these targets. We can also measure how this alleviates cellular toxicity and brain cell death.'

"Importantly our research techniques could have application in assisting to find drug targets for other neurodegenerative diseases where toxic clusters of proteins play a role in the progression of the disease, such as for Parkinson's disease."


'/>"/>

Contact: Rebecca Scott
rebeccas@unimelb.edu.au
61-383-440-181
University of Melbourne
Source:Eurekalert

Related biology news :

1. UM researcher identifies novel treatment for pain in sickle cell disease
2. U of T researchers find link between childhood physical abuse and heart disease
3. Protein important in diabetes may also play a key role in heart disease, other disorders
4. Research results confirm need for protection against ticks that carry Lyme disease
5. Dairy farmers can fight growing disease threat with chlorine and stainless steel
6. Disease genes that followed the Silk Road identified
7. Scientists discover clues to inflammatory disease
8. Waterborne diseases could cost over $500 million annually in US
9. Plavix may be treatment for dogs at risk of thromboembolic disease
10. Modulator of fetal hemoglobin switch may target sickle cell disease
11. Mount Sinai researchers discover new way diseases develop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
(Date:6/22/2016)... 2016   StockNewsNow.com , The Official MicroCap News ... Nader Pourhassan , President & CEO of CytoDyn ... clinical development and potential commercialization of humanized monoclonal antibodies ... to the company,s website (see here: www.CytoDyn.com ). ... th , 2016, at the LD Micro Invitational in ...
(Date:6/22/2016)... June 22, 2016  Mesa Biotech Inc., a ... testing platform designed specifically for point-of-care (POC) infectious ... scientific advisory board (SAB). Approved by the executive ... is chartered to advise on the development and ... Led by Dr. Steve Young , this ...
Breaking Biology Technology: